Eli Lilly & Co. (LLY) announced Friday that it plans to manufacture its experimental weight-loss pill in the U.S. as President Trump emphasizes reshoring manufacturing to the U.S. “We’re going to make this medicine here in the United States,

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes.

The first GLP-1 pill could be in medicine cabinets sooner than expected. Eli Lilly (LLY) announced Thursday that its daily obesity pill, orforglipron, met company goals in the first of several late-stage trials — helping patients with Type 2 diabetes lower their blood sugar while causing weight loss.